Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 A lyophilized formulation of RiVax, a recombinant ricin subunit vaccine, retains immunogenicity.

Literature DB >> 20074685

A lyophilized formulation of RiVax, a recombinant ricin subunit vaccine, retains immunogenicity.

Abstract

Ricin is a CDC level B biothreat. Our recombinant ricin A chain vaccine (RiVax) contains two mutations, rendering it non-toxic at high doses. Frozen or alum formulations of RiVax protected mice against ricin administered by injection, gavage or aerosol. Without alum, RiVax was safe and immunogenic in rabbits and human volunteers. For military use, the predominant target group, it would be optimal not to require a cold chain for transport and storage. We have now developed a lyophilized formulation and demonstrated stability and efficacy for at least 1 year stored refrigerated or at room temperature administered with or without alum.

Entities: CellLine Chemical Disease Gene Mutation Species

Mesh：

Substances：

Year: 2010 PMID： 20074685 PMCID： PMC2839540 DOI： 10.1016/j.vaccine.2009.12.081

Source DB: PubMed Journal: Vaccine ISSN： 0264-410X Impact factor: 3.641

28 in total

1. Potency of clinical group B streptococcal conjugate vaccines.

Authors: L C Paoletti
Journal: Vaccine Date: 2001-02-28 Impact factor: 3.641

2. Influenza vaccine powder formulation development: spray-freeze-drying and stability evaluation.

Authors: Yuh-Fun Maa; Mahmoud Ameri; Cassandra Shu; Lendon G Payne; Dexiang Chen
Journal: J Pharm Sci Date: 2004-07 Impact factor: 3.534

3. A rapid, three-step process for the preformulation of a recombinant ricin toxin A-chain vaccine.

Authors: Laura J Peek; Robert N Brey; C Russell Middaugh
Journal: J Pharm Sci Date: 2007-01 Impact factor: 3.534

4. Preclinical toxicity and efficacy testing of RiVax, a recombinant protein vaccine against ricin.

Authors: Joan E Smallshaw; James A Richardson; Seth Pincus; John Schindler; Ellen S Vitetta
Journal: Vaccine Date: 2005-09-15 Impact factor: 3.641

5. RiVax, a recombinant ricin subunit vaccine, protects mice against ricin delivered by gavage or aerosol.

Authors: Joan E Smallshaw; James A Richardson; Ellen S Vitetta
Journal: Vaccine Date: 2007-08-30 Impact factor: 3.641

Review 6. Ricin poisoning: a comprehensive review.

Authors: Jennifer Audi; Martin Belson; Manish Patel; Joshua Schier; John Osterloh
Journal: JAMA Date: 2005-11-09 Impact factor: 56.272

7. Stabilization of alum-adjuvanted vaccine dry powder formulations: mechanism and application.

Authors: Yuh-Fun Maa; Lu Zhao; Lendon G Payne; Dexiang Chen
Journal: J Pharm Sci Date: 2003-02 Impact factor: 3.534

Review 8. Development of stable influenza vaccine powder formulations: challenges and possibilities.

Authors: J-P Amorij; A Huckriede; J Wilschut; H W Frijlink; W L J Hinrichs
Journal: Pharm Res Date: 2008-06 Impact factor: 4.200

9. A pilot clinical trial of a recombinant ricin vaccine in normal humans.

Authors: Ellen S Vitetta; Joan E Smallshaw; Elaine Coleman; Hasan Jafri; Callie Foster; Robert Munford; John Schindler
Journal: Proc Natl Acad Sci U S A Date: 2006-02-03 Impact factor: 11.205

10. A novel recombinant vaccine which protects mice against ricin intoxication.

Authors: Joan E Smallshaw; Ana Firan; John R Fulmer; Stephen L Ruback; Victor Ghetie; Ellen S Vitetta
Journal: Vaccine Date: 2002-09-10 Impact factor: 3.641

14 in total

1. Plant ribosome-inactivating proteins type II induce the unfolded protein response in human cancer cells.

Authors: C Horrix; Z Raviv; E Flescher; C Voss; M R Berger
Journal: Cell Mol Life Sci Date: 2010-09-16 Impact factor: 9.261

2. A recombinant chimeric protein containing B chains of ricin and abrin is an effective vaccine candidate.

Authors: Junhong Wang; Shan Gao; Tao Zhang; Lin Kang; Wuchun Cao; Na Xu; Wensen Liu; Jinglin Wang
Journal: Hum Vaccin Immunother Date: 2014-02-07 Impact factor: 3.452

3. Enhancing Efficacy and Stability of an Antiheroin Vaccine: Examination of Antinociception, Opioid Binding Profile, and Lethality.

Authors: Candy S Hwang; Paul T Bremer; Cody J Wenthur; Sam On Ho; SuMing Chiang; Beverly Ellis; Bin Zhou; Gary Fujii; Kim D Janda
Journal: Mol Pharm Date: 2018-02-19 Impact factor: 4.939

4. Intradermal administration of RiVax protects mice from mucosal and systemic ricin intoxication.

Authors: Praveena S Marconescu; Joan E Smallshaw; Laurentiu M Pop; Stephen L Ruback; Ellen S Vitetta
Journal: Vaccine Date: 2010-06-01 Impact factor: 3.641

5. Thermostable ricin vaccine protects rhesus macaques against aerosolized ricin: Epitope-specific neutralizing antibodies correlate with protection.

Authors: Chad J Roy; Robert N Brey; Nicholas J Mantis; Kelly Mapes; Iliodora V Pop; Laurentiu M Pop; Stephen Ruback; Stephanie Z Killeen; Lara Doyle-Meyers; Heather S Vinet-Oliphant; Peter J Didier; Ellen S Vitetta
Journal: Proc Natl Acad Sci U S A Date: 2015-03-09 Impact factor: 11.205

6. Stabilization of a recombinant ricin toxin A subunit vaccine through lyophilization.

Authors: Kimberly J Hassett; Megan C Cousins; Lilia A Rabia; Chrystal M Chadwick; Joanne M O'Hara; Pradyot Nandi; Robert N Brey; Nicholas J Mantis; John F Carpenter; Theodore W Randolph
Journal: Eur J Pharm Biopharm Date: 2013-04-10 Impact factor: 5.571